SCHEMBL2026124

SCHEMBL2026124

O=C(OC[C@H]1C[C@H](O)[C@@H](F)C1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.45
PRMT6 Q96LA8 1/20 0.45
CHRNB2 P17787 1/20 0.44
CHRNA5 P30532 1/20 0.44
CHRNA7 P36544 1/20 0.44
CHRNA4 P43681 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
NPC1 O15118 1/20 0.43
KMT2A Q03164 2/20 0.42
MAPK1 P28482 1/20 0.42
HIF1A Q16665 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
PPM1B O75688 1/20 0.41
LMNA P02545 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CES2 O00748 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2021058 1.00 CARM1 (0.45) CARM1PRMT6CHRNB2CHRNA5CHRNA7
SCHEMBL2515294 1.00 CARM1 (0.45) CARM1PRMT6CHRNB2CHRNA5CHRNA7
SCHEMBL2026126 1.00 CARM1 (0.45) CARM1PRMT6CHRNB2CHRNA5CHRNA7
SCHEMBL2509616 1.00 CARM1 (0.45) CARM1PRMT6CHRNB2CHRNA5CHRNA7
SCHEMBL2514162 1.00 CARM1 (0.45) CARM1PRMT6CHRNB2CHRNA5CHRNA7
SCHEMBL2021055 1.00 CARM1 (0.45) CARM1PRMT6CHRNB2CHRNA5CHRNA7
SCHEMBL2515295 1.00 CARM1 (0.45) CARM1PRMT6CHRNB2CHRNA5CHRNA7
SCHEMBL2509615 1.00 CARM1 (0.45) CARM1PRMT6CHRNB2CHRNA5CHRNA7
SCHEMBL2019099 0.91 CARM1 (0.49) CARM1PRMT6CHRNB2CHRNA5CHRNA7
SCHEMBL2511239 0.91 CARM1 (0.49) CARM1PRMT6CHRNB2CHRNA5CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452977-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2016-09-27 US disclosed
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2015-04-16 US disclosed
US-8946440-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US disclosed
US-8173649-B2 Glucokinase activator KYORIN PHARMACEUTICAL CO., LTD. (JP) 2012-05-08 US disclosed
US-8034819-B2 Glucokinase activator KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-10-11 US disclosed
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2011-06-30 US disclosed
US-20100016304-A1 GLUCOKINASE ACTIVATOR TEIJIN LIMITED (JP) 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016304-A1 GLUCOKINASE ACTIVATOR GCK, GCKR, GALK1 CARM1 1951/4885PRMT6 912/4885CHRNB2 4453/4885
US-20110160211-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE GPR119, SLC5A1, SLC5A2 CARM1 1165/4885PRMT6 772/4885CHRNB2 4413/4885
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE GPR119, SLC5A1, SLC5A2 CARM1 1165/4885PRMT6 772/4885CHRNB2 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.